tiprankstipranks
Novo Nordisk (DE:NOVC)
XETRA:NOVC

Novo Nordisk (NOVC) Stock Forecast & Price Target

9 Followers
See the Price Targets and Ratings of:

NOVC Analyst Ratings

Moderate Buy
12Ratings
7 Buy
3 Hold
2 Sell
Based on 12 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NOVC Stock 12 Months Forecast

Average Price Target

€137.01
▲(51.01% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €137.01 with a high forecast of €207.78 and a low forecast of €89.14. The average price target represents a 51.01% change from the last price of €90.73.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"€88","118":"€118","148":"€148","178":"€178","208":"€208"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":207.7762445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€207.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.0089961152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€137.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.14271135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€89.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,118,148,178,208],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Sep<br/>2023","25":"Sep<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.06,177.5766341923077,180.09326838461539,182.60990257692308,185.12653676923077,187.64317096153846,190.15980515384615,192.67643934615384,195.19307353846153,197.70970773076922,200.22634192307692,202.7429761153846,205.2596103076923,{"y":207.7762445,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.06,172.13299970116924,169.20599940233848,166.2789991035077,163.35199880467692,160.42499850584616,157.4979982070154,154.5709979081846,151.64399760935385,148.71699731052308,145.78999701169232,142.86299671286156,139.93599641403077,{"y":137.0089961152,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.06,168.45097779615384,161.8419555923077,155.23293338846153,148.6239111846154,142.01488898076923,135.40586677692306,128.79684457307692,122.18782236923077,115.57880016538462,108.96977796153847,102.36075575769232,95.75173355384615,{"y":89.14271135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":105.952,"date":1662681600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.656,"date":1665100800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.284,"date":1667520000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.164,"date":1669939200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.386,"date":1672963200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.437,"date":1675382400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.094,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.909,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.482,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.273,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.705,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.888,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.06,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€207.78Average Price Target€137.01Lowest Price Target€89.14
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Credit Suisse
€167.56
Buy
84.68%
Upside
Reiterated
07/11/23
Stifel Nicolaus
€171.58
Buy
89.11%
Upside
Reiterated
04/14/23
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,280 at StifelStifel analyst Eric Le Berrigaud raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,280.00 (from DKK1,205.00) while maintaining a Buy rating.
Citi
€160.86
Buy
77.29%
Upside
Reiterated
03/30/23
Citi Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)Citi analyst Peter Verdult reiterated a Buy rating and DKK1,200.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).
Goldman Sachs
€160.86
Buy
77.29%
Upside
Reiterated
02/13/23
Oddo BHF
€121.98
Buy
34.45%
Upside
Upgraded
09/28/22
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHFNovo Nordisk upgraded to Outperform from Neutral at Oddo BHF

Best Analysts Covering Novo Nordisk

Which Analyst Should I Follow If I Want to Buy DE:NOVC and Sell After:
1 Month
Keyur ParekhGoldman Sachs
Success Rate
27/38 ratings generated profit
71%
Average Return
+2.25%
reiterated a buy rating a year ago
Copying Keyur Parekh's trades and holding each position for 1 Month would result in 71.05% of your transactions generating a profit, with an average return of +2.25% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Wimal KapadiaBernstein
Success Rate
16/20 ratings generated profit
80%
Average Return
+7.80%
reiterated a buy rating 2 years ago
Copying Wimal Kapadia's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +7.80% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Emily FieldBarclays
Success Rate
22/22 ratings generated profit
100%
Average Return
+40.70%
reiterated a buy rating 7 months ago
Copying Emily Field's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +40.70% per trade.
2 Years
Keyur ParekhGoldman Sachs
Success Rate
38/38 ratings generated profit
100%
Average Return
+85.75%
reiterated a buy rating a year ago
Copying Keyur Parekh's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +85.75% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOVC Analyst Recommendation Trends

Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

NOVC Financial Forecast

NOVC Earnings Forecast

Next quarter’s earnings estimate for NOVC is €0.61 with a range of €0.57 to €0.71. The previous quarter’s EPS was €0.58. NOVC beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.40% of the time in the same period. In the last calendar year NOVC has Outperformed its overall industry.
Next quarter’s earnings estimate for NOVC is €0.61 with a range of €0.57 to €0.71. The previous quarter’s EPS was €0.58. NOVC beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.40% of the time in the same period. In the last calendar year NOVC has Outperformed its overall industry.

NOVC Sales Forecast

Next quarter’s sales forecast for NOVC is €7.60B with a range of €7.14B to €8.21B. The previous quarter’s sales results were €7.29B. NOVC beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 60.00% of the time in the same period. In the last calendar year NOVC has Outperformed its overall industry.
Next quarter’s sales forecast for NOVC is €7.60B with a range of €7.14B to €8.21B. The previous quarter’s sales results were €7.29B. NOVC beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 60.00% of the time in the same period. In the last calendar year NOVC has Outperformed its overall industry.

NOVC Stock Forecast FAQ

What is DE:NOVC’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is €137.01.
    What is DE:NOVC’s upside potential, based on the analysts’ average price target?
    Novo Nordisk has 51.01% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Novo Nordisk a Buy, Sell or Hold?
          Novo Nordisk has a conensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 2 sell ratings.
            What is Novo Nordisk’s share price target?
            The average share price target for Novo Nordisk is €137.01. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €207.78 ,and the lowest forecast is €89.14. The average share price target represents 51.01% Increase from the current price of €90.73.
              What do analysts say about Novo Nordisk?
              Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Novo Nordisk?
                To buy shares of DE:NOVC, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis